ALNY – alnylam pharmaceuticals, inc. (US:NASDAQ)

News

Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by analysts at Weiss Ratings from a "sell (d-)" rating to a "hold (c-)" rating.
JPM26: 2025 a “breakout year” for rare disease biotechs [Yahoo! Finance]
Alnylam Pharmaceuticals (ALNY) Is Down 9.0% After Ambitious 2026 Guidance And 2030 Plan Reveal [Yahoo! Finance]
Adimab Reports Strong Partnering Year for 2025 [Yahoo! Finance]
Alnylam Pharmaceuticals Unveils “Alnylam 2030” as Amvuttra Drives Breakout Growth at JPMorgan Conf. [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com